Approval based on pivotal Phase 3 C-POST trial showing Libtayo significantly reduced the risk of disease recurrence or death by 68% compared to placebo (hazard ratio: 0.32; 95% confidence interval: 0.
The Second World Congress on Targeting Extracellular Vesicles (EVs) is scheduled for 15–16 October 2025 in Valencia, Spain. This landmark event, co-organized by the World Mitochondria Society and the ...
Oral Presentation at ESGCT Highlights Potential of JCR’s Proprietary JUST-AAV Platform to Facilitate More Efficient Delivery While Reducing Liver Tropism-HYOGO, Japan--(BUSINESS WIRE)--JCR ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback